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Abstract
Background: Clostridium difficile infection (CDI) has emerged as a rapidly growing problem associated with
the widespread use of broad-spectrum antibiotics. These antibiotics disrupt the natural bacterial flora in the
colon and create an opportunity for C. difficile to invade and multiply. Current treatment with oral
vancomycin and metronidazole is effective in many cases, however up to 35% of patients experience a relapse
of CDI after completion of treatment, placing them at increased risk for recurrent C. difficile infections
(RCDIs). Alternative therapies consist of probiotic and immunotherapy treatments, which are helpful in
preventing CDI, but not at stopping the infection once it exists. Surgery is also an option, however it has many
serious implications. Recently, fecal bacteriotherapy, or stool transplantation, has been successful at
eradicating RCDI. Fecal bacteriotherapy uses the complete normal human flora as a therapeutic probiotic
mixture of living organisms, transporting the healthy flora from a donor to a recipient with RCDI. The
therapeutic use of fecal bacteriotherapy in the treatment of RCDI is reviewed here.
Methods: A systematic review was conducted using Medline, EBSCOhost and Web of Science, utilizing the
keywords Clostridium difficile, bacteriotherapy and pseudomembranous colitis. Relevant articles were found
and cross-referenced; references were reviewed for additional pertinent materials. At the time of this review,
there are no RCTs published, therefore this review focuses on case series and case reports.
Results: Four case reports and case studies were reviewed and include a total of 26 patients. Each patient had
at least two recurrences of CDI prior to receiving fecal bacteriotherapy treatment. Eighteen patients received
treatment through the upper GI tract via nasogastric tube, while eight patients received therapy through the
lower GI tract via colonoscope or fecal enema. Most patients were treated in the outpatient setting. Treatment
response was similar in all methodologies, with patients reporting a decrease in diarrhea almost immediately.
All patients, except one, remained free from any CDI recurrence through the follow-up period of 90 days to
five years.
Conclusion: RCDI is an increasing problem in our medical community. Very difficult to treat, it takes a heavy
toll on both patients and providers. Other treatment options, such as probiotics and immunotherapy, have
had minimal successes. Fecal bacteriotherapy is a safe, rapid and highly effective option for the treatment of
RCDI. Despite inadequacies in the current published literature, the studies appraised in this review support
the therapeutic benefits of fecal bacteriotherapy for the treatment or RCDI and suggest potential for this
inexpensive and minimally-risky treatment modality to undergo further investigations for clinical use.
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Abstract   
 
Background:  Clostridium difficile infection (CDI) has emerged as a rapidly growing 
problem associated with the widespread use of broad-spectrum antibiotics.  These 
antibiotics disrupt the natural bacterial flora in the colon and create an opportunity for C. 
difficile to invade and multiply.  Current treatment with oral vancomycin and 
metronidazole is effective in many cases, however up to 35% of patients experience a 
relapse of CDI after completion of treatment, placing them at increased risk for recurrent 
C. difficile infections (RCDIs).  Alternative therapies consist of probiotic and 
immunotherapy treatments, which are helpful in preventing CDI, but not at stopping the 
infection once it exists.  Surgery is also an option, however it has many serious 
implications.  Recently, fecal bacteriotherapy, or stool transplantation, has been 
successful at eradicating RCDI.  Fecal bacteriotherapy uses the complete normal human 
flora as a therapeutic probiotic mixture of living organisms, transporting the healthy flora 
from a donor to a recipient with RCDI.  The therapeutic use of fecal bacteriotherapy in 
the treatment of RCDI is reviewed here. 
Methods:  A systematic review was conducted using Medline, EBSCOhost and Web of 
Science, utilizing the keywords Clostridium difficile, bacteriotherapy and 
pseudomembranous colitis.  Relevant articles were found and cross-referenced; 
references were reviewed for additional pertinent materials.  At the time of this review, 
there are no RCTs published, therefore this review focuses on case series and case 
reports.   
Results:  Four case reports and case studies were reviewed and include a total of 26 
patients.  Each patient had at least two recurrences of CDI prior to receiving fecal 
bacteriotherapy treatment.  Eighteen patients received treatment through the upper GI 
tract via nasogastric tube, while eight patients received therapy through the lower GI tract 
via colonoscope or fecal enema.  Most patients were treated in the outpatient setting.  
Treatment response was similar in all methodologies, with patients reporting a decrease 
in diarrhea almost immediately.  All patients, except one, remained free from any CDI 
recurrence through the follow-up period of 90 days to five years.   
Conclusion:  RCDI is an increasing problem in our medical community.  Very difficult 
to treat, it takes a heavy toll on both patients and providers.  Other treatment options, 
such as probiotics and immunotherapy, have had minimal successes.  Fecal 
bacteriotherapy is a safe, rapid and highly effective option for the treatment of RCDI.  
Despite inadequacies in the current published literature, the studies appraised in this 
review support the therapeutic benefits of fecal bacteriotherapy for the treatment or RCDI 
and suggest potential for this inexpensive and minimally-risky treatment modality to 
undergo further investigations for clinical use.   
Keywords:  Clostridium difficile, fecal bacteriotherapy, stool transplants, 
pseudomembranous colitis 
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Fecal Bacteriotherapy for the Treatment of Recurrent Clostridium 
Difficile Infection in Adults 
 
BACKGROUND  
 Diarrhea is a common side effect of the administration of antibiotics, with 
Clostridium difficile (C. difficile) being responsible for most of the severe cases of 
antibiotic-associated diarrhea, including the development of pseudomembranous colitis.1-
3  The incidence of infection with C. difficile is rapidly increasing worldwide consequent 
to the widespread use of broad-spectrum antibiotics.  Population data from Quebec has 
shown the instance of Clostridium difficile –associated diarrhea (CDAD) has increased 
from 35.6 cases per 100 000 in 1991 to 156.3 per 100 000 in 2003.4  In the United States, 
C. difficile infections (CDI) are projected to reach 450 000-750 000 cases per year by the 
end of 2010.5,6  Infection severity has also increased, with the percentage of cases defined 
as complicated, increasing from 7.1% in 1991-92 to 18.2% in 2003.  A ten-fold increase 
in incidence in patients older than 65 years has also occurred during this same time 
period.4  In 2000, Kyne et al7 found that 31% of patients who received antibiotics in an 
acute care setting were colonized with C. difficile, and 56% of these patients developed 
CDAD.7  Furthermore, persons affected by CDAD are more likely to suffer recurrent C. 
difficile infections (RCDI).8   
Conservative estimates suggest that patients with CDAD incur at least $3669 
extra in hospital costs and spend at least 3.6 additional days hospitalized.9  O’Brien et al10 
studied 1034 CDI cases in Massachusetts during 2000, concluding the average cost 
associated with each case of CDI was between $10 212 and $13 675 per instance, 
creating a national cost of $3.2 billion per year for the treatment of CDI alone.  With 
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instance and cost associated with CDAD rising dramatically, a reliable treatment 
modality must be found.   
Etiology  
Clostridium difficile is an anaerobic, gram-positive, spore-forming, toxin-
producing bacillus that was first described in 1935.11  It was not until the late 1970s, 
however, that the C. difficile toxin was found in the stools of patients with antibiotic-
associated diarrhea (AAD) and pseudomembranous colitis (PMC).12  Clostridium difficile 
can exist in both spore and vegetative forms.  Outside the colon, C. difficile lives in its 
spore form, which is commonly found in soil, the general environment, pets, untreated 
water, and in some raw vegetables.13  These spores, which are resistant to heat, acid 
(including gastric acid) and chemical agents such as antibiotics and disinfectant, can 
survive for months on surfaces such as bed rails, stethoscopes, skin folds and the hands of 
caregivers.14  Inside the colon, the spores convert to their fully functional vegetative, 
toxin-producing forms and can be destroyed by antimicrobial agents.  Vegetative forms 
have been found in the intestinal tracts of animals, including household pets.13  
Pathophysiology 
Two potent exotoxins that mediate colitis and diarrhea are released by 
Clostridium difficile, toxin A (an enterotoxin) and a more potent toxin B (a 
cytotoxin).15,16  Toxin A activates macrophages and mast cells, which release 
inflammatory mediators. 17  These mediators disrupt the cell wall, increase the 
permeability of the intestinal wall and lead to intestinal fluid secretion and diarrhea, 
which in itself causes mucosal injury and inflammation.18  Toxin B is approximately ten 
times more potent than toxin A with respect to propagating colonic mucosal damage.16  It 
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degrades epithelial cells in the colon, causing colitis.  As the colitis worsens, purulent and 
necrotic debris accumulates and forms characteristic ulcers, the pseudomembranes.15,17  A 
new, hypervirulent strain of C. difficile, NAPI/BI/027, has been implicated as the 
responsible pathogen in the dramatic increase of C. difficile infection (CDI) since the 
early 2000s.4  It is more virulent and can produce 16 times greater quantities of toxin A 
and 23 times greater quantities of toxin B.18  The epidemic strain also produces binary 
toxin, a toxin related to the iota-toxin found in Clostridium perfringens, however, its role 
in C. difficile is not fully understood.4,18  This binary toxin is resistant to 
fluoroquinolones, a situation which did not occur in other C. difficile strains prior to 
2001.4   
 Transmission of C. difficile occurs via the fecal-oral route.  The infected human 
gut and the contaminated hospital environment remain the most important reservoir for 
the organism.  Clostridium difficile has been isolated from health care workers’ hands; in 
fact, hand transmission is thought to be the most important factor in the acquisition and 
spread of C. difficile in hospitalized patients.14  In healthy individuals, the growth of C. 
difficile is kept in check by normal flora in the gut.  The use of antibiotics and 
medications that decrease stomach acidity, such as proton pump inhibitors, can cause C. 
difficile bacteria to flourish.19  The mechanisms by which antibiotic administration leads 
to the development of CDAD are not yet entirely clear.  The human gut is colonized by a 
diverse community of microorganisms that exist in a complex symbiosis with its host.20  
Approximately 20% of hospitalized adults are C. difficile carriers; in long term care 
facilities, this number may approach 50%.14,21  Although asymptomatic, these carriers 
shed pathogenic organisms and serve as a reservoir for environmental contamination.14,21   
 10 
 The native flora in the gut are a primary defense mechanism which prohibit the 
pathogen colonization.  The resident flora produce antimicrobial factors which compete 
for nutrients in the matrix and binding sites on the epithelium.22  The mechanisms by 
which antimicrobial agents induce intestinal disease associated with C. difficile are still 
not known.  These drugs may alter the normal bacterial flora of the gastrointestinal (GI) 
tract so as to permit colonization and/or proliferation of C. difficile and toxin elaboration 
by the organism.  Clostridium difficile appears to flourish when the competing bacterial 
flora are suppressed.22  After an initial insult on gut flora by antibiotics, C. difficile and 
other pathogens have the ability to invade and multiply.  Current treatment regimes for 
CDI involve stopping the offending antibiotic, eradicating the C. difficile spores to 
prohibit multiplication and ultimately replenishing the natural flora of the gut.   
Clinical Manifestations 
 Clostridium difficile-associated diarrhea can be mild, severe or systemic.  Mild 
disease is characterized by non-bloody diarrhea, occasionally accompanied by cramping 
in the lower part of the abdomen, but without systemic signs or symptoms.  The diarrhea, 
often mucoid and foul smelling, can be accompanied by nausea, dehydration, low grade 
fever and possible leukocytosis.18  Colitis occurs with severe forms of CDAD and causes 
profuse watery diarrhea up to 10 to 15 times daily, with lower abdominal cramping, 
dehydration, low grade fever and leukocytosis.18  Characteristic raised white and yellow 
plaques may be visible during sigmoidoscopy.3,18  The presence of pseudomembranes is 
considered sufficient to make a presumptive diagnosis of C. difficile.23  Complications 
such as sepsis, volume depletion, electrolyte imbalances, hypotension, peritonitis, 
paralytic ileus and toxic megacolon may be present in systemic CDAD.18,23   
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Current Treatment Modalities 
 Standard treatment for CDAD involves the administration of antibiotics that 
suppress C. difficile, such as metronidazole or vancomycin.  Although the majority of 
cases will respond initially to either drug, recurrence after the discontinuation of the 
medication can occur.24  Furthermore, risk of CDI doubles after three days of antibiotic 
therapy.  Recurrent C. difficile infection (RCDI) can be defined as the reappearance of 
symptoms within eight to ten weeks after the termination of specific antibiotic therapy 
and is best confirmed with a positive diagnostic test for CDI.25  Between 20 to 25% of 
patients experience a recurrence of symptoms after the initial episode of CDI has 
resolved.26  Up to 45% of those with one recurrence of CDI will go on to suffer further 
recurrences,27 and up to 65% will relapse after two or more recurrences.28     
The current antibiotic therapy protocol for the treatment of RCDI includes 
stopping the causative antibiotic, if possible, and placing the patient on vancomycin and 
metronidazole.29,30  Although generally effective in achieving a clinical recovery, the use 
of an antibiotic, such as vancomycin, does not restore the gut microflora, nor does it 
reduce the exposure to C. difficile in the environment, the comorbidity, or other host risk 
factors.  Up to 25% of patients develop another episode of diarrheal disease within two 
months.1,30  Although some of these recurrent cases may be caused by ongoing exposure 
to C. difficile spores in the environment, most are due to the bacterial strain that caused 
the original episode, reflecting a lack of efficacy of antibiotic treatment in eliminating the 
C. difficile spores from the gut.29,30  Kelly and LaMont31 show the recurrence rates after 
treatment with vancomycin and metronidazole are similar, 18.4% and 20.8%, 
respectively.  These numbers have increased, however, since the year 2000.  Before 2000, 
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vancomycin had a recurrence rate of 17.9%, with a slight rise to 19.9% after 2000.  
Metronidazole has shown a much more dramatic increase of 6.7% prior to and 28.6% 
recurrence after the year 2000.31  This raises the question concerning the role of 
alternative treatments for CDI, adjunctive to current standard antimicrobial treatment 
with vancomycin or metronidazole.   
Probiotics have long been studied in the prevention and treatment of CDI.  
Administration of antibiotics disrupts the balance of microorganisms in the gut; patients 
with RCDI have shown markedly diminished bacterial diversity compared to controls.32  
Probiotics restore the gut’s colonization resistance by providing a barrier of relatively 
low-virulence microorganisms – mainly yeasts or Lactobacillus species – that compete 
with C. difficile for essential nutrients and mucosal adherence sites.  Limited data suggest 
that probiotics may play a useful role in treatment of CDAD, particularly in the setting of 
recurrent disease, although there is no data that probiotics have a role in the treatment of 
severe CDAD.33,34  In a 2006 meta-analysis of probiotics for the treatment of CDAD, 
including six randomized controlled trials involving 354 patients, Saccharomyces 
boulardii was the only effective probiotic agent for reducing the recurrence of CDAD.33  
In a 2008 Cochrane review of probiotics for the treatment of CDAD, including four 
randomized trials, the authors concluded that there was insufficient evidence to 
recommend probiotics as an adjunct to antimicrobial therapy for treatment of CDAD.34   
Recently, questions have been raised as to the safety associated with introducing 
live organisms into an immunocompromised gut.  In 2009, McFarland35 reviewed the use 
of probiotics for the treatment of AAD and CDI.  Risks associated with probiotics include 
(1) the transfer of antibiotic-resistant genes (2) translocation of the living organism from 
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the intestine to other areas of the body and (3) persistence in the intestines or the 
development of adverse reactions relating to interactions with the host’s microflora.  Her 
extensive review purports most clinical trials of AAD and CDI have not detailed any 
serious adverse reactions that can be linked with the use of probiotics.  Side effects of 
probiotics have been mild to moderate reactions, namely nausea, vomiting, abdominal 
cramping or pain, rash, diarrhea or constipation.  Of note, frequencies of reported adverse 
reactions are rarely higher than those reported by the control groups.  McFarland found 
12 cases of Lactobacillus bacteremia and 24 cases of fungemia in patients taking 
Lactobacillus and S. boulardii, respectively, mostly in severely ill patients.35  
Translocation of the living organism has been found only in animal models if the animal 
has been immunocompromised.36  Finally, many bacterial and yeast products do not 
contain the exact makeup stated on the outside of the bottle.  There is a lack of stringent 
quality control regulations for food and dietary supplements.  Many probiotic products 
are not regulated and are manufactured in uncontrolled environments, opening the 
possibility for other strains of bacteria and yeast to enter the product, or not enough 
bacteria being present to ensure the patient receives the proper effective dose.35,37   
 Another treatment option is the use of intravenous immunoglobulin (IVIG) for the 
treatment of RCDI.  Although there is questionable evidence that immunity against C. 
difficile infection exists, there appears to be an association between a systemic response 
to the presence of toxin A and CDAD development.   In an analysis of patients colonized 
with C. difficile, patients who remained asymptomatic had significantly larger increases 
in serum antitoxin A immunoglobulin (Ig) G than those who developed CDAD 
(p<0.001).7  Therefore, increasing antitoxin A IgG levels may result in increased 
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asymptomatic C. difficile carriage and decreased progression to CDAD, although the 
mechanism leading to the different pathological courses is unknown.  Even though 
favorable outcomes have been reported, no data from randomized, controlled trials are 
available.  Additional trials, with greater power and therapy regime standardization, are 
needed to fully evaluate this treatment option.   
Surgery, most often colectomy, is a last-resort treatment for severe to fulminant, 
life-threatening CDAD.  Severe CDAD is defined as CDAD with any evidence of 
systemic inflammatory response syndrome indicated by the presence of one or more of 
the following: temperature >38◦C or <36◦C, tachycardia of >90 beats per minute, 
tachypnea of >20 breaths per minute, pCO2 of < 4.26 kPa (32 mmHg), leukocyte count of 
<4000 or >12 000, or the presence of >10% immature neutrophils.38  Fulminant CDAD is 
defined by the manifestation of any of the following: heart rate >120 beats/minute, >30% 
immature neutrophils, decline in respiratory status requiring mechanical ventilation, 
immunosupression, oliguria, prior bowel surgery unrelated to prior CDAD occurrence 
and hypotension requiring vasopressors.39  Both severe and fulminant CDAD can result 
in bowel perforation, toxic megacolon and peritonitis, each carrying a high mortality 
rate.23  In 2002, Dallal et al39 found a death rate of 57% in patients with colitis status post 
colectomy.  This high rate reflects a critically ill patient population and possible 
contribution to mortality from accompanying CDAD.  Furthermore, no patient over the 
age of 80 years survived the surgery.  Koss et al23 found an overall mortality rate of 
35.7% in their analysis of surgery in fulminant C. difficile colitis.  While these mortality 
rates may seem rather high, the risk of bowel perforation and toxic megacolon are also 
associated with dramatic mortality rates.  Early surgical intervention, and thorough 
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evaluation of the predictors of survival, is necessary for the best possible treatment 
outcomes. 
Fecal Bacteriotherapy 
 An alternative approach to probiotics or surgery, fecal bacteriotherapy utilizes the 
complete normal human flora as a therapeutic probiotics mixture of living organisms.  
Fecal bacteriotherapy refers to the process of instilling a liquid suspension of stool from a 
healthy donor into the gastrointestinal (GI) tract of the recipient.  The stool sample may 
be collected on the day of transplantation from a patient’s spouse, household contact or 
an unrelated donor.24,40-42  Prior to collection, the sample donor is typically screened for 
potentially contagious infectious agents.24  After collection, the stool sample is processed 
in the clinical laboratory into a liquid suspension, and is subsequently instilled into the 
upper GI tract through a nasogastric (NG) tube or into the colon through a colonoscope or 
a retention enema catheter.24,40-42   
 Fecal bacteriotherapy has been shown to be quite effective.  The first investigators 
to report the successful use of fecal enemas in the management of four patients with 
pseudomembranous colitis (PMC) occurred in 1953.43  Since then, numerous articles 
have been published touting the almost instantaneous success of fecal bacteriotherapy in 
the treatment of RCDI.  If this treatment modality has been shown to be so effective, why 
is its use not more prevalent?  In 2009, Bakken8 conducted a literature review on the use 
of fecal bacteriotherapy to treat RCDI.  In his review, however, Bakken included all 
research available on the topic, including studies that examined the role of fecal 
bacteriotherapy as treatment for other diseases such as irritable bowel syndrome.  This 
systematic review will examine the literature addressing fecal bacteriotherapy as 
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treatment of RCDI specifically, in adults who have failed antibiotic therapy, looking for 
the halt of diarrhea and the decreased instance of CDI recurrence.   
 
METHODS 
This systematic review appraises the current research and literature published on 
the treatment of recurrent Clostridium difficile infections (RCDI) with fecal 
bacteriotherapy.  A comprehensive literature search was conducted utilizing the Medline 
(via OVID), EBSCOhost (via CINAHL) and Web of Science databases.  The keywords 
Clostridium difficile, bacteriotherapy and pseudomembranous colitis yielded nine 
references from Medline, four from EBSCOhost and twenty-four from Web of Science.  
Relevant articles were selected and cross-referenced for additional materials.  All 
references of pertinent literature were reviewed, with relevant articles being included in 
this review.  At the time this review was conducted, there were no randomized control 
studies published; therefore this review will focus on case series and case reports.   
All compiled references were analyzed for pertinence with the following criteria: 
articles evaluating adult patients with RCDI that were treated with fecal bacteriotherapy 
or stool transplant, as well as the instance of diarrhea and recurrence of CDI following 
treatment as outcomes were included in this review.  Exclusion criteria included patients 
younger than 18 years old and studies that did not assess the effect of treatment on C. 
difficile directly.  Materials unavailable in English were excluded.  Articles published in 
non-peer-reviewed format, such as letters to the editor, were not included despite their 
relevancy to this topic, as it is difficult to evaluate their accuracy and accountability.  
Authors of such literature were contacted to determine if their material was available in 
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published format.  Literature with only the abstract published and those which were 
unable to be obtained in full text were also excluded.   
 
RESULTS 
 A total of thirty-seven articles were found using Medline, EBSCOhost and Web 
of Science.  An additional five related studies were identified while reviewing the 
references of the original articles.  After inclusion and exclusion criteria were applied, a 
total of five articles remained; however, one had to be excluded as only the abstract was 
published.  The remaining four articles24,40-42 were assessed to ensure their patient 
population, interventions and measured outcomes were all consistent with the goals of 
this review (See Table 1: Matrix of Reviewed Literature).  The articles were then 
thoroughly reviewed and their validity was scored according to the criteria illustrated in 
Table 2: Validity Matrix.  Prior to rating the articles, it was decided that articles with a 
validity of three or greater would be included; at the end of this exhaustive literature 
search and review process, four articles were included in this review.  
 In Sweden, Schwan et al,41 published a case report of a 67 year old female who 
was successfully treated with fecal bacteriotherapy via enema.  The patient had a lifelong 
history of irritable colon, developing into diverticulosis and subsequent diverticulitis 
which ultimately had to be treated with a sigmoid colectomy.  The patient was treated 
prophylactically with antibiotics prior to the resection.  One week after the surgery, the 
patient developed bilateral pneumonia and pleuritis, for which she was treated with 
trimethoprim/sulfamethoxazole and recovered without incident.  Two weeks later, the 
patient began experiencing frequent diarrhea and febrile illness with a C. difficile-positive 
 18 
stool sample.  Oral vancomycin successfully treated this initial C. difficile infection 
(CDI), however, two weeks after ending treatment, the patient experienced a recurrence 
of CDI confirmed with a stool sample.  The patient was again treated with vancomycin, 
and the infection resolved.  The patient had four more recurrent C. difficile infections 
(RCDIs) over the next six months, even after prolonged (four week) treatment with 
vancomycin.  Probiotics were utilized in two separate instances, as adjuvant therapy, 
without any obvious effect.  The patient was finally treated with fecal bacteriotherapy.  
Her husband donated his stool which was screened for salmonella, shigella, Yersenia 
enterocolitica, Staphylococcus aureus, Campylobacter jejuni and C. difficile.  The stool 
was prepared as outlined in the original article.  The patient then received the stool 
mixture as an enema which was not evacuated for more than 24 hours after the procedure.  
Three days later, a second enema was given, which was not evacuated for six hours.  The 
fecal bacteriotherapy treatment resulted in “prompt and complete normalization of the 
bowel function”.41   The patient was followed for more than a year, during which she had 
no recurrence of CDI.  She did experience slight GI disturbances related to her irritable 
colon, however, not to the extent previously experienced.  The patient also gained six 
kilograms of weight.41   
 Tvede et al42 conducted a case report of six patients in Denmark with chronic 
RCDI who were treated with fecal bacteriotherapy.  The patients, five females and one 
male aged 59 to 83 years, had each had at least two diagnosed relapses of CDI after the 
initial infection.  A chart is included in the original source, detailing each patient’s 
specific preceding infection and treatment regimen.  Initially, two patients were treated 
with a fecal enema and four with bacteriotherapy.  The bacteriotherapy treatment 
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consisted of rectal instillation of a mixture of ten different faculatative aerobic and 
anaerobic bacteria species that had been cultured in the laboratory and diluted in sterile 
saline.  These bacterial species included Streptococcus (Enterococcus) faecalis, 
Clostridium innoctutum, C. ramnosum, C. bifermentans, Bactroides ovatus, B. vulgatus, 
B. thetaiotaomicro, Escherichia coli (two separate strains), and  Peptostreptococcus  
productus.  On the day of treatment, two patients were given fecal enemas of stool 
donated by family members.  The other four patients were given rectal enema of the 
bacterial mixture.  One patient was not responsive to the fecal enema and was 
consequently treated with bacteriotherapy.  All cases of CDI were ultimately resolved.  
Rapid resolution of diarrhea and normalization of serum albumin and serum orosomucoid 
concentrations occurred.  Stool cultures and toxin assays for C. difficile remained 
negative for the year-long follow-up of all patients.42   
 In the United States, Persky et al40 describe a case report of a 60 year old woman 
who had been experiencing RCDIs for six months and was successfully treated with stool 
transplantation via colonoscope.  This previously healthy patient presented with severe 
left lower quadrant pain and was found to have multiple sigmoid diverticula surrounded 
by inflammatory changes.  She was hospitalized and treated with intravenous ceftazidime 
and metronidazole.  While her abdominal pain resolved, she developed AAD while in the 
hospital.  Stool cultures were initially negative for C. difficile, and the patient was 
discharged on oral cefaclor and metronidazole to finish the treatment for diverticulitis.  
Her diarrhea persisted and the antibiotics were discontinued.  Subsequent stool samples 
were positive for C. difficile.  The diarrhea resolved with metronidazole, but returned less 
than one week after the cessation of treatment.  Repeat CDI were resolved with courses 
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of vancomycin.  A presumed recurrent episode of diverticulitis was treated with 
amoxicillin/clavulanate, sparking another CDI.  The patient then endured several months 
of oral vancomycin therapy (over $17 000 worth) without improvement in her condition.  
The patient presented to Montefiore Medical Center and was treated with stool 
transplantation with stool donated by her husband.  The donor was not tested for hepatitis 
A, B or C, or for HIV as the donor and patient had been in a monogamous relationship 
for over 30 years.  The stool was not tested for any pathogen either as the donor did not 
have any GI complaints.  The patient’s colon was prepared with a cleansing lavage and a 
500 ml infusion of the donor stool was distributed evenly every 10 cm throughout the 
colon utilizing a colonoscope.  The patient had immediate and complete resolution of 
diarrhea and was negative for the C. difficile toxin on subsequent stool assays on follow 
up.  The patient has remained free of diarrhea and CDI for five years.40   
 Aas et al24 published a retrospective case series of 18 patients in Deluth, 
Minnesota who received donor stool transplants (ST) through a nasogastric (NG) tube for 
RCDI.  These patients all received treatment from the same physician between June 1994 
and August 2002.  Study participants included 13 women and five men, ages 51 to 88 
years, with a history of RCDI.  Five of the patients were hospitalized at the time of ST, 
while the rest were treated in an outpatient gastroenterology clinic.  The study’s inclusion 
criteria consisted of a laboratory-confirmed diagnosis of C. difficile colitis, two or more 
laboratory-confirmed relapses of C. difficile colitis after treatment with a specific initial 
antimicrobial and sufficient clinical and laboratory documentation, by either telephone or 
chart review, of the patient’s course of health after the stool transplantation.  Stool donors 
had not received any antimicrobial therapy in the six months preceding donation.  
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Donors, in order of preference, were individuals who had intimate physical contact with 
the patient, such as a spouse or partner, family household members, or any other healthy 
donor.  Donors’ blood was screened for hepatitis A, B and C viruses; HIV-1 and HIV-2; 
and syphilis.  Donor stool samples were screened for C. difficile, enteric bacterial 
pathogens, ova and parasites.  Fifteen of the donors were members of the recipients’ 
families, while the remaining three received stool from a healthy clinic staff volunteer.  
Preparation of stool transplant (ST) specimens is outlined in the original source.  Prior to 
the ST, patients were prophylaxed with at least a four-day course of antibiotics to reduce 
the amount of C. difficile in the colon; treatment was discontinued the evening before the 
ST.  Patients were also prophylaxed with omeprazole the evening before and day of the 
procedure.  During the procedure, a NG tube was placed into the patient’s stomach, with 
the tip position confirmed by abdominal radiography.  Twenty-five milliliters of the 
transplant stool was infused and flushed with saline.  Patients were able to resume normal 
diet and physical activity immediately.  Two patients died shortly after the ST from 
diseases unrelated to the C. difficile or ST.  One patient did have a recurrence of diarrhea 
17 days after ST, which was negative for C. difficile.  He was treated with vancomycin 
and all symptoms resolved.  He had no further recurrences and continued to test negative 
for C. difficile over the next six months.  Fourteen of the 16 surviving patients tested 
negative for C. difficile in stool samples taken within 30 days of the ST.  The other two 
patients did not submit samples, but they were contacted and denied any return of 
diarrhea or other symptoms following the ST.  All patients remained diarrhea free during 
the 90 day follow-up period.24 
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DISCUSSION 
 The primary goal of this review is to appraise the current research and literature 
available on the use of fecal bacteriotherapy in the treatment of recurrent C. difficile 
infection (RCDI).  The four included studies24,40-42 took place between 1984 and 2003 in 
Denmark, Sweden and the United States.  A total of 26 patients were included, 20 
females and five males, aged 51 to 88 years.  Each patient had at least two recurrences of 
C. difficile infection (CDI) prior to receiving fecal bacteriotherapy treatment.  Most 
patients received treatment in the outpatient setting.  Eighteen patients were given stool 
transplants (ST) through the upper gastrointestinal (GI) tract via nasogastric (NG) tube,24 
while eight patients received therapy through the lower GI tract via colonoscope or fecal 
enema.40-42  Treatment response was almost immediate, with patients reporting a decrease 
in diarrhea within 24 hours in most cases.  All but one patient had success with the 
treatment, and that patient was quickly cured with one course of antimicrobial therapy 
without recurrence.24  Two patients died soon after ST from unrelated causes.24  A 
summation of these studies can be found in Table 3: Summary of Findings.   
Overall, the success of treatment with fecal bacteriotherapy was remarkable.  
Including the two deceased patients in the patient total, but not as cured, 23 of the 26 
patients were cured with fecal bacteriotherapy, a cure rate of 88.5%.  If these two patients 
are excluded, 23 of the 24 patients had successful treatments, with 95.8% cured.  Only 
one of the patients experienced a recurrence of CDI during of follow-up period as 
evidenced by a positive stool sample, and even that recurrence was quickly responsive to 
antibiotics and did not occur again.24  None of the other patients experienced RCDI 
during the follow-up period of 90 days to five years.  These numbers are quite dramatic 
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compared to the 65% relapse rate after being treated two or more times with antibiotics or 
a mortality rate of almost 36% following colectomy for treatment of RCDI, as discussed 
above.  Probiotics have proven useful in the prevention of recurrence of CDI, however, 
they are quite ineffective once CDI has occurred.  Immunoglobulin research remains in 
the preliminary phases, but looks somewhat promising.  The exact mechanisms of fecal 
bacteriotherapy in the treatment of CDI are unclear, but probably involve the 
recolonization of colonic flora with missing components to regenerate colonization 
resistance.44  Unlike the transient use of antibiotics and antimicrobials, directly 
implanting fecal flora provides a lengthy exposure of “antagonistic” activity that not only 
cures the current infection, but also prevents future colonization by C. difficile, 
presumably by restoring flora colonization resistance.44  Fecal bacteriotherapy shows 
much potential in the treatment of RCDI, however, there are many refinements to the 
research, proven efficacy and procedures that need to take place before the therapy can 
become commonly used.   
One major limitation to the validity of these studies was the size of the studies 
themselves.  In this review, two of the included studies each had only one participant,40,41 
while the other two had six participants42 and 18 participants.24  This, in large part, is due 
to the fact that these were retrospective case reviews and therefore not pre-planned with 
actively recruited participants.  Also, fecal bacteriotherapy remains a relatively unknown 
and underutilized treatment modality.   Interest in this area is growing, however.  In 
December 2009, Rubin et al45 submitted a letter to the editor detailing their successes in 
treating 61 patients with RCDI with fecal bacteriotherapy since 2003.  Unfortunately, 
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their data has not been published formally, and was therefore ineligible for inclusion in 
this review.  New studies are being devised and initiated with larger patient populations.   
Although transmission of communicable disease has not been reported after fecal 
infusions, lingering concern remains as to the potential spread of infectious agents 
contained in the fecal sample from stool donors to recipients.  The literature included in 
this review varied widely in how this risk was minimized.  Aas et al24 had the most 
stringent screening processes with a clearly stated donor screening protocol, as reviewed 
above.  Schwan et al41 tested the donor feces a total of eight different times in the three 
weeks preceding ST.  The feces were negative for parasitic and bacterial pathogens as 
detailed above, but the donor’s blood was not reported to have been tested.  This may 
have been omitted as the donor was the patient’s husband; however, the blood screening 
of donors was not addressed in the study.41  Persky et al40 openly stated their donor, the 
recipient’s husband, was not tested for hepatitis or HIV as the couple had been in a 
monogamous relationship for 30 years, nor was the stool tested for common pathogens as 
the donor “did not have any GI complaints”.40  The authors do, however, strongly 
recommend the routine testing of all donors prior to the initiation of stool donation.  
Tvede et al42 had a detailed report of bacterial strains cultured from study participants, 
but made no mention of screening either donor blood or fecal samples.  The variance of 
screening protocols permits a substantial risk of the passage of infection during ST, even 
in donor/patient relationships in which it is likely any exposure has already taken place.  
This risk may be reduced by obtaining stool from healthy donors with normal bowel 
function and by testing both donor stool and blood for common viral and bacterial 
pathogens and parasites.  In a 2004 review of fecal bacteriotherapy, Borody et al2 
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suggested donors should be treated much the same way as traditional organ donors.  In 
addition to being free of antimicrobial therapy for at least three to six months prior to 
donation, donors should have a complete blood count and liver function tests performed.  
Serological testing should be negative for hepatitis A, B and C; HIV-1 and HIV-2; 
cytomegalovirus; Epstein-Barr virus and syphilis.  Furthermore, stool should be negative 
for any detectable parasites, ova or bacterial pathogens.2  Selecting a patient’s spouse or 
significant other has the theoretical advantage that any transmissible disease should have 
emerged well before treatment with ST.  Regardless, the selection of relatives or spouses 
as fecal donors should not preclude the necessity for thorough screening, just as blood 
donations should not be transfused until properly screened for infectious disease.   
Treatment with fecal bacteriotherapy has been hindered by a lack of 
standardization in the preparation and administration of the actual fecal suspension.  Even 
among the four studies included in this review, significant variations exist in the 
protocols for fecal infusion.  Aas et al24 clearly outline their methods for not only the 
preparation of donor stool samples prior to ST, but also the preparation of the ST 
recipient and description of the transplantation procedure.  The donor stool sample was 
obtained within six hours of the ST.  Approximately 30 grams of the stool specimen were 
blended with 50-70 milliliters of sterile 0.9% NaCl.  The suspension was filtered, and 
refiltered, through a paper coffee filter.  A NG tube was placed in the recipient 
immediately prior to ST, with confirmation of placement via radiography.  Twenty-five 
milliliters of the stool suspension was infused via the NG tube, the tube was flushed with 
NaCl and then withdrawn.24  Tvede et al42 elaborately describe the preparation of the 
bacterial mixture for fecal instillation in the original literature.  The fecal enema was 
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prepared by mixing fifty grams of the donor stool in 500 milliliters of saline.  The 
procedure for fecal instillation was not described.42  The stool sample for the patient 
reported by Schwan et al41 was transported to the laboratory in a sterile glass container 
within 20 minutes after passing.  The feces was suspended in approximately 100 
milliliters of sterile 0.15 M NaCl and sieved through a strainer several times.  A quantity 
of 450 milliliters of the stool suspension was inserted into the patient as an enema.41  
Persky et al40 were not as diligent in relating their stool sample preparations and ST 
procedure.  The patient was prepped for colonoscopy with 1 gallon of Golytely as a 
cleansing lavage.  During the colonoscopy, a “500-ml infusion comprised of stool 
(donated from the patient’s husband) mixed with saline was uniformly injected every 10 
cm throughout her colon”.40  In summary, stool samples varying in size from 30 to 50 
grams, were mixed with 50 to 500 milliliters of various concentrations of saline, and 
anywhere from 25 to 500 milliliters of stool suspension were inserted in the patient (see 
Table 4: Fecal Infusion Constituents).  In their review of fecal bacteriotherapy, Borody et 
al2 conclude low doses of fecal mass used in treatment may have less effect and that 
severe disease may require a higher therapeutic dose to fully eradicate infection.  Further 
research is necessary to determine the ideal concentration of stool specimen to ensure 
optimal results in the fewest number of therapy sessions necessary for resolution of CDI.   
The efficacy of fecal bacteriotherapy appears to depend on a number of factors 
including the freshness of the donated stool, the frequency and route of fecal 
administration, and the repopulation of the entire colon.  It is generally agreed upon that 
the freshness of the stool is important; timely placement of the transplant reduces the 
likelihood of foreign pathogens being introduced into the sample, as well as ensuring the 
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healthy flora do not expire outside their native environment.  Neither the length of time 
between the donation of the stool and the mixing of the stool infusion, nor the length of 
time between the mixing of the stool infusion and instillation of the infusion has yet to be 
studied.  Current transplantation protocol calls for stool transplantation within six hours 
of the passing of the donor stool; however, there is much variance in actual timeliness of 
separate studies.24,25  The number of fecal instillations necessary to cure a patient also 
remains ambiguous at this time.  As discussed above, this may correlate with the amount 
of fecal mass transplanted in a single treatment.  The method of placement may also 
contribute to the success of the ST; instillation of donor feces can be accomplished from 
either the proximal or the distal end of the GI tract.  In this review, most ST were 
performed via the upper GI tract, however, Bakken reports most occur via the lower GI 
tract.8  Donated stool administered by enema is not optimal as it only reaches the splenic 
flexure, theoretically allowing proliferation of spores proximal to the splenic flexure.40  
Colonoscope placement of donor stool suspension seems to allow the entire colon to be 
treated and replenished, decreasing the recurrence of CDI after ST.40  Fecal instillation 
via colonoscope is associated with an increased risk of complications, such as colon 
perforation, than other methods.8  This is partly due to the inflamed, and therefore friable, 
state of the colon.  Preparation of the colon with a cleanser such as Golytely is preferable 
to allow room for the movement of the colonoscope and direct instillation of the fecal 
suspension.  ST via the lower GI tract requires a larger volume of fecal suspension to 
allow for seepage through the rectum and often requires multiple instillations over several 
days to reach success.8  One advantage of ST via colonoscope is the ability to fully 
visualize the entire colon and to look at pathology for further clues as to the cause of 
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relapse.40  The use of NG tubes for fecal instillation has several purported advantages.  
The placement of a NG tube is quite simple, requiring little, if any sedation.  Unlike 
colonoscope instillation, there is no preparation needed for a NG tube, which is 
advantageous in dehydrated or severely ill patients.  A smaller fecal sample is needed for 
NG placement as there will be no leakage of the sample.  Associated complications 
include possible perforation of the esophagus, although less likely than a colonic 
perforation, and possible aspiration of fecal matter.8  Finally, there is limited cost 
associated with NG assisted ST as the only radiology costs are to ensure the tip of the 
infusion catheter is in the correct position.24  Future studies need to directly compare ST 
via NG tube, fecal enemas and colonoscope placement in the reduction of CDI incidence.  
Treatment protocol for the use of fecal bacteriotherapy for RCDI should be standardized.     
Preparation of the colon prior to fecal bacteriotherapy with antimicrobials, acid 
reducers and/or cleansing of the colon may be helpful in increasing the efficacy of the 
procedure and reducing the need for multiple infusions.  Pretreatment with oral 
antibiotics, such as vancomycin, prior to the ST reduce the number of vegetative C. 
difficile colonies.8  Aas et al24 reported success following pretreatment with oral 
vancomycin for four or more days before subsequent infusion of stool via a NG tube into 
the stomach in a series of patients with multiple relapses.  A clinical response was 
observed within 12 to 24 hours.  The pretreatment with antibiotics, however, makes it 
impossible to determine whether the antibiotics or the ST halted CDI and prevented 
recurrence.  The fact that these patients have had RCDIs with the previous use of 
antibiotics may suggest the ST is more effective at long term cure rates.24  Another aspect 
of protocol worthy of further research is the use of acid reducers, such as proton pump 
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inhibitors, just before the procedure to decrease gastric hydrochloric acid production and 
to create an optimal environment for the instilled fecal bacteria to implant.8,24  Finally, 
colonic lavage with agents such as Golytely, has been suggested prior to ST via the lower 
GI tract.  Cleansing may reduce the density of C. difficile organisms including the 
metabolically inactive spores, which could otherwise convert to vegetative (active) 
forms.40  Colonic lavage is a risky procedure in a severely ill patient as the risk of 
dehydration is great in patients of suboptimal health.  Research is needed to determine 
whether this step truly aids in the success of the fecal instillation, or whether it can be 
disregarded in severely ill patients, but still maintain success of the procedure.    
 The next step in solidifying the use of fecal bacteriotherapy in the treatment of 
RCDI is to conduct randomized control trials (RCT) to conclusively demonstrate the 
efficacy of the therapy.  RCTs help reduce the instance of bias; for example, reporting 
bias can occur with overestimation of a treatment effect because of failure to randomize 
and recall bias cannot be accounted for when there is no control group of patients to 
compare the report of adverse events.46  In a RCT, participants are randomly allocated to 
receive or not to receive an experimental therapeutic procedure and then followed to 
determine the effect of the intervention.  A true RCT may be difficult to assemble as 
finding a placebo resembling fecal matter to blind both patients and clinicians may be 
quite challenging.  No RCTs have been completed or published to date, however, several 
are ongoing47 both in the United States and abroad.  In the Netherlands, the FECAL 
(Faecal therapy to Eliminate Clostridium difficile-Associated Longstanding diarrhea) 
trial25 is underway to assess whether restoring the intestinal flora in patients with 
recurrent CDAD by feces from a healthy donor can prevent future recurrences.  This 
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RCT compares donor feces infusion to conventional antibiotic treatment with oral 
vancomycin.  Initiated in January, 2008, this study was scheduled to close at the end of 
2009.  Results from this study have yet to be published, but look promising as the study 
appears to be a well-planned, protocol-driven, double-blind RCT.   
 
CONCLUSION 
Clostridium difficile infection (CDI) is a rapidly increasing problem worldwide, 
both in and out of the hospital setting.  The instance of recurrence is growing as the 
organism becomes resistant to antibiotic treatment, which in itself provides the 
opportunity for C. difficile to inhabit the colon as the natural flora of the gut are 
disturbed.  Recurrent C. difficile infection (RCDI) takes a heavy toll on the patients, 
hospitals and providers, insurance agencies and the economy as antimicrobial therapy is 
expensive and patients lose more time working from worsening, debilitating illness.  
Other treatment options, such as adjuvant therapy of probiotics and immunotherapy have 
had minimal successes – especially in moderate to severe CDI – and surgery remains a 
risky last-choice option.  Fecal bacteriotherapy is a safe, rapid and highly effective option 
for the treatment of RCDI.  Despite inadequacies in current study designs, the literature 
appraised in this review adds support to the therapeutic benefits of fecal bacteriotherapy 
for the treatment of RCDI and suggests potential for this inexpensive and minimally-risky 
treatment modality to undergo further investigations for clinical use.   
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Tables 
Table 1: Matrix of Reviewed Literature 
Author/ 
Ref # 
Year 
 
Patients/ 
Population 
Intervention Comparison Outcome(s) Study 
Type 
Validity 
Score 
(Out of 5) 
Aas24 
 
2003 Adults with 
recurrent 
CDI 
Given donor 
stool by 
nasogastric tube 
None Prompt halt of 
diarrhea.  
No CDI 
recurrence. 
Case 
Series 
4 
Persky40 2000 Adult with 
recurrent 
CDI 
Donor stool via 
colonoscope 
None Prompt halt of 
diarrhea.   
No CDI 
recurrence. 
Case 
Report 
3 
Schwan41 1984 Adult with 
recurrent 
CDI 
Donor stool 
given via 2 
enemas  
None Prompt halt of 
diarrhea. 
No CDI 
recurrence. 
Weight gain. 
Case 
Report 
4 
Tvede42 1989 Adults with 
recurrent 
CDI 
Donor stool via 
enema or 
bacteriotherapy 
None Prompt halt of 
diarrhea. 
No CDI 
recurrence. 
Weight gain. 
Case 
Series 
4 
 
 
 
Table 2: Validity Matrix 
Author/ 
Ref # 
Lab-
Confirmed 
Diagnosis 
of CDI 
≥2 Lab-
Confirmed 
Relapses of 
CDI After 
Initial Abx 
Treatment 
Failed ≥2 
Treatment 
Methodsa 
Fecal 
Testing 
Within 
30 Days 
of ST 
≥ 90 
Day 
Follow-
Up 
Validity 
Score 
(Out of 5) 
Comments 
Aas24 1 1 0 1 1 4 Tx with abx 
Persky40 1 1 0 0b 1 3 Tx with abx 
 
Schwan41 1 1 1 0 1 4 Tx with abx, 
probiotics 
Serum testing, 
not fecal 
Tvede42 1 1 0 1 1 4 Tx with abx 
a Treatment methods to include antibiotics, probiotics, immunotherapy 
b Had negative CD test, but unknown how long after ST 
 
Abx – Antibiotics   ST – Stool Transplant 
CD – Clostridium difficile   Tx - Treatment 
CDI – Clostridium difficile Infection  
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Table 3: Summary of Findings 
Author/ 
Ref. # 
Year/ 
Location 
Cases 
(n) 
Sex of 
Patients 
Age 
Range 
(Years) 
# of Relapses 
 Prior      After 
To ST       ST 
Inpatient/ 
Outpatient 
Who Donated 
the Stool 
Method 
of 
Delivery 
Number 
of ST 
Received 
Cure 
(%) 
Follow
-up 
Time 
Commenta 
Aas24 2003 
US 
 
18 13 F 
5 M 
51-88 2-7 17 = 0 
1=1 
3/15 15 – Family 
member 
3 – Volunteer 
staff 
Upper 
GI Tract 
1 15 
(83.3) 
90 
days 
1 treatment 
failure 
2 deaths from 
unrelated 
illnesses 
Persky40 2000 
US 
1 1 F 60 4 0 Unknown Husband Lower 
GI Tract 
 
1 1  
(100) 
5 years Golytely lavage 
ST via colono-
scope 
Schwan41 1984 
Sweden 
1 1 F 67 5 0 1/0 Husband Lower 
GI Tract 
2 1  
(100) 
1 year 3 days between 
enemas 
Tvede42 1989 
Denmark 
6b 5 F 
1 M 
59-83 2-4 0 Unknown 2 – Family 
5 – Bacterial 
Suspensionc 
Lower 
GI Tracta 
1 (2 a) 6  
(100) 
6-12 
months 
See additional 
information 
below 
Total - 26 20 F 
6 M 
51-88 2-7 25=0 
1=1 
4/15 
7 Unknown 
19 – Family 
3 – Volunteer 
5 – Bacterial 
Suspensionc 
18-Upper 
8-Lower 
1-2 23 
(88.5)d 
(99.5)e 
 
90 
days – 
5 years 
See additional 
information 
below 
a Limitations include no randomization of patients, no blinding and no control groups in all studies 
b Initially, two patients were treated with fecal enema and four with bacteriotherapy.  One patient was not responsive to the fecal enema and was treated with 
bacteriotherapy at a later date. 
c The bacteriotherapy treatment consisted of rectal instillation of a mixture of ten different faculatative aerobic and anaerobic bacteria species diluted in sterile saline.  
These bacterial species included Streptococcus (Enterococcus) faecalis, Clostridium innoctutum, C. ramnosum, C. bifermentans, Bactroides ovatus, B. vulgatus, B. 
thetaiotaomicro, Escherichia coli (two separate strains), and Peptostreptococcus productus.    
d Percent cure including the two deaths from unrelated illnesses 
e Percent cure excluding the two deaths from unrelated illnesses
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Table 4: Fecal Infusion Constituents  
Author/ Ref # Stool Sample Size Mixing Solution Amount Infused 
Aas24 30 g 50-75 ml 0.9% NaCl 25 ml 
Persky40 Unknown Unknown 500 ml 
Schwan41 Unknown 100 ml 0.15 M NaCl 450 ml 
Tvede42 50 g 500 ml Saline Unknown 
Total 30 – 50 g 50 – 500 ml 25-500 ml 
 
 
 
 
  
 
 
